Genomics and Bioinformatics Group web site development and maintenance

我们目前正在过渡到虚拟服务器，并更新我们的安全状态，以符合日益严格的政府要求。我们成功地维护和扩展了大部分基于网络的Discover工具，重点是CellMiner和CellMinerCDB。我们的CellMiner“NCI-60分析工具”部分仍然是药物基因组学整合，研究和发现的重要资源。它目前是四种工具的宿主，i）“细胞系特征”，ii）“交叉相关”，iii）“模式比较”，和iv）“药物与基因变体/同种型变体”，所有这些都旨在减少科学家整合分子和药理学数据所需的时间。我们将继续升级本部分的软件和数据库。目前，我们提供了任何大规模细胞数据库中最具包容性的分子和最大化合物活性数据集。CellMiner的数据和工具正在为癌症患者的合理药物发现、应用和个性化治疗创造重大机遇。由于许多类型的分子改变可以有助于治疗的结果，基因组和药理学设施（GPF）管理和整合分子和药理学数据，以增强理解，并促进可检验假设的生成。因此，GPF既提供了对高吞吐量数据的访问，又提供了便于挖掘、理解和利用该数据的软件资源。由于DTP药物数据库包含未开发的化合物和药物，因此它仍然是识别潜在新药和提高对现有药物的理解的无与伦比的资源。NCI-60是迄今为止最全面的哺乳动物细胞图谱。CellMiner CDB扩展了这种方法，包括额外的数据库，允许用户随意挖掘和集成。目前，我们的Discover和CellMiner网站每月有来自110个国家的9，400名个人用户。它在过去和现在继续导致翻译发现。

We are currently in the midst a transition to virtual servers, and an update of our security status to comply with the increasingly stringent government requirements. We have successfully maintained and expanded the bulk of our Discover web-based tools, with emphasis on CellMiner and CellMinerCDB. Our CellMiner "NCI-60 Analysis Tools" section remains a significant resource for pharmacogenomic integration, research, and discovery. It is currently the host for four tools, i) "Cell line signature", ii) Cross-correlation", iii) Pattern comparison", and iv) "Drug vs gene variant/isoforms variant", all of which are designed to reduce the time required by the scientist to integrate molecular and pharmacological data. We continue to upgrade both the software and databases in this section. We currently provide the most inclusive set of molecular and largest compound activity data among any of the large-scale cellular databases. The CellMiner data and tools are creating major opportunities for progress in rational drug discovery, application, and individualization of therapy for cancer patients. As molecular alterations of many types can contribute to the outcome of therapy, the Genomic and Pharmacolgy Facility (GPF) manages and integrates molecular and pharmacological data in such a way that enhances understanding, and facilitates the generation of testable hypotheses. The GPF thus both provides access to high throughput data, and provides software resources that facilitate the mining, understanding, and exploitation of that data. As the DTP drug database contains both unexplored compounds and drugs, it remains an unmatched resource both for recognition of potential novel drugs, and improving understanding of pre-existing ones. The NCI-60 is by far the most comprehensively profiled panel of mammalian cells anywhere. CellMiner CDB expands this approach to include addition databases allowing the user to mine and integrate at will. Currently our Discover and CellMiner sites have 9,400 individual users from 110 countries per month. It has in the past and currently continues to lead to translational discoveries.